Agrawal S. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma. World J Clin Oncol 2017; 8(3): 255-260 [PMID: 28638795 DOI: 10.5306/wjco.v8.i3.255]
Corresponding Author of This Article
Shefali Agrawal, MD, MS, FACS, Senior Consultant, Hepatobiliary and Pancreatic Surgery, Department of Surgical Oncology, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi 110076, India. shefali_a@apollohospitals.com
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 10, 2017; 8(3): 255-260 Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.255
Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
Shefali Agrawal
Shefali Agrawal, Hepatobiliary and Pancreatic Surgery, Department of Surgical Oncology, Indraprastha Apollo Hospitals, New Delhi 110076, India
Author contributions: Agrawal S solely contributed to this paper.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Shefali Agrawal, MD, MS, FACS, Senior Consultant, Hepatobiliary and Pancreatic Surgery, Department of Surgical Oncology, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi 110076, India. shefali_a@apollohospitals.com
Telephone: +91-81-30009660
Received: December 15, 2016 Peer-review started: December 19, 2016 First decision: March 27, 2017 Revised: April 1, 2017 Accepted: May 12, 2017 Article in press: May 13, 2017 Published online: June 10, 2017 Processing time: 168 Days and 8.5 Hours
Core Tip
Core tip: Pancreatic juice is a rich source of cancer-specific proteins rendering it a promising tool for identifying novel biomarkers in pancreatic ductal adenocarcinoma. Recent proteomic and microRNA expression analyses have identified several diagnostic and prognostic biomarkers. Elevated carcinoembryonic antigen (CEA) in bile is a marker of malignancy and a predictor of hepatic recurrence. The potential of cancer antigen 19-9, CEA and lactate dehydrogenase as prognostic biomarkers in pancreatic juice and bile is unknown. Specimens of pancreatic juice and bile can be readily collected during pancreatic resection. Profiling of pancreatic juice and bile to identify novel biomarkers may facilitate early diagnosis and improve selection of patients for adjuvant therapy.
